Aortic stenosis in chronic kidney disease: challenges in diagnosis and treatment

Heart ◽  
2021 ◽  
pp. heartjnl-2021-319604
Author(s):  
Jessica I Gupta ◽  
Sarah K Gualano ◽  
Nicole Bhave

Chronic kidney disease (CKD) is becoming increasingly common and is associated with development and rapid progression of aortic stenosis (AS). Patients with AS and CKD have higher mortality rates than those with AS of similar severity and normal kidney function. The diagnosis of severe AS in patients with CKD is often challenging due to alterations in haemodynamics and heart structure, and integration of data from multiple imaging modalities may be required. When indicated, the definitive treatment for severe AS is aortic valve replacement. Patients with CKD are candidates for bioprosthetic valve replacement (surgical or transcatheter aortic valve implantation) or mechanical valve replacement. However, for patients with CKD, lifetime management is complex, as patients with CKD have a higher competing risk of bioprosthetic structural valve deterioration, bleeding in the setting of systemic anticoagulation and mortality related to CKD itself. The involvement of a heart-kidney multidisciplinary team in the care of patients with CKD and severe AS is ideal to navigate the complexities of diagnosis and management decisions.

Circulation ◽  
2021 ◽  
Author(s):  
Gautam R. Shroff ◽  
Sripal Bangalore ◽  
Nicole M. Bhave ◽  
Tara I. Chang ◽  
Santiago Garcia ◽  
...  

Aortic stenosis with concomitant chronic kidney disease (CKD) represents a clinical challenge. Aortic stenosis is more prevalent and progresses more rapidly and unpredictably in CKD, and the presence of CKD is associated with worse short-term and long-term outcomes after aortic valve replacement. Because patients with advanced CKD and end-stage kidney disease have been excluded from randomized trials, clinicians need to make complex management decisions in this population that are based on retrospective and observational evidence. This statement summarizes the epidemiological and pathophysiological characteristics of aortic stenosis in the context of CKD, evaluates the nuances and prognostic information provided by noninvasive cardiovascular imaging with echocardiography and advanced imaging techniques, and outlines the special risks in this population. Furthermore, this statement provides a critical review of the existing literature pertaining to clinical outcomes of surgical versus transcatheter aortic valve replacement in this high-risk population to help guide clinical decision making in the choice of aortic valve replacement and specific prosthesis. Finally, this statement provides an approach to the perioperative management of these patients, with special attention to a multidisciplinary heart-kidney collaborative team-based approach.


2020 ◽  
Vol 9 (19) ◽  
Author(s):  
Yohann Bohbot ◽  
Alexandre Candellier ◽  
Momar Diouf ◽  
Dan Rusinaru ◽  
Alexandre Altes ◽  
...  

Background The prognostic significance of chronic kidney disease (CKD) in severe aortic stenosis is poorly understood and no studies have yet evaluated the effect of aortic‐valve replacement (AVR) versus conservative management on long‐term mortality by stage of CKD. Methods and Results We included 4119 patients with severe aortic stenosis. The population was divided into 4 groups according to the baseline estimated glomerular filtration rate: no CKD, mild CKD, moderate CKD, and severe CKD. The 5‐year survival rate was 71±1% for patients without CKD, 62±2% for those with mild CKD, 54±3% for those with moderate CKD, and 34±4% for those with severe CKD ( P <0.001). By multivariable analysis, patients with moderate or severe CKD had a significantly higher risk of all‐cause (hazard ratio [HR] [95% CI]=1.36 [1.08–1.71]; P =0.009 and HR [95% CI]=2.16 [1.67–2.79]; P <0.001, respectively) and cardiovascular mortality (HR [95% CI]=1.39 [1.03–1.88]; P =0.031 and HR [95% CI]=1.69 [1.18–2.41]; P =0.004, respectively) than patients without CKD. Despite more symptoms, AVR was less frequent in moderate ( P =0.002) and severe CKD ( P <0.001). AVR was associated with a marked reduction in all‐cause and cardiovascular mortality versus conservative management for each CKD group (all P <0.001). The joint‐test showed no interaction between AVR and CKD stages ( P =0.676) indicating a nondifferentialeffect of AVR across stages of CKD. After propensity matching, AVR was still associated with substantially better survival for each CKD stage relative to conservative management (all P <0.0017). Conclusions In severe aortic stenosis, moderate and severe CKD are associated with increased mortality and decreased referral to AVR. AVR markedly reduces all‐cause and cardiovascular mortality, regardless of the CKD stage. Therefore, CKD should not discourage physicians from considering AVR.


2018 ◽  
Vol 93 (4) ◽  
pp. 740-748 ◽  
Author(s):  
Andres M. Pineda ◽  
J. Kevin Harrison ◽  
Neal S. Kleiman ◽  
Michael J. Reardon ◽  
John V. Conte ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document